Valliant John 4
4 · Fusion Pharmaceuticals Inc. · Filed Apr 22, 2022
Insider Transaction Report
Form 4
Valliant John
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2022-04-21$6.01/sh−922$5,541→ 326,841 total - Sale
Common Stock
2022-04-20$6.02/sh−367$2,209→ 327,763 total
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
- [F2]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.02 to $6.03 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.00 to $6.05 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.